The role of androgens in follicle maturation and ovulation induction: Friend or foe of infertility treatment?

Reproductive Biology and Endocrinology

Volumn 9, Issue , 2011, Pages

  Gleicher, Norbert ^a,b,c   Weghofer, Andrea ^a,d   Barad, David H ^a,b,e  

^a Center for Human Reproduction New York   (United States)

^b Foundation for Reproductive Medicine   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

^e ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; FOLLITROPIN; PRASTERONE; TESTOSTERONE; GONADOTROPIN;

ANDROGEN SYNTHESIS; FEMALE FERTILITY; FEMALE SUBFERTILITY; GRANULOSA CELL; HORMONE ACTION; HUMAN; INFERTILITY THERAPY; NONHUMAN; OVARIAN RESERVE; OVARY FOLLICLE DEVELOPMENT; OVARY FOLLICLE MATURATION; OVULATION INDUCTION; REVIEW; TRANSCRIPTION REGULATION; ANIMAL; DRUG EFFECT; FEMALE; FEMALE INFERTILITY; METHODOLOGY; OVARY; OVARY FOLLICLE; OVARY POLYCYSTIC DISEASE; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALIA;

ANDROGENS; ANIMALS; DEHYDROEPIANDROSTERONE; FEMALE; FOLLICLE STIMULATING HORMONE; GONADOTROPINS; HUMANS; INFERTILITY, FEMALE; OVARIAN FOLLICLE; OVARY; OVULATION INDUCTION; POLYCYSTIC OVARY SYNDROME; RECEPTORS, ANDROGEN;

EID: 80051647739     PISSN: None     EISSN: 14777827     Source Type: Journal    
DOI: 10.1186/1477-7827-9-116     Document Type: Review

References (102)

1. Smith DM, Tenney DY. Effects of steroids on mouse oocyte maturation in vitro. J Reprod Fertil 1980, 60:;331-338. 10.1530/jrf.0.0600331, 7431352.
2. Eppig JJ, Freter RR, Ward Bailey PF, Schultz RM. Inhibition of oocyte maturation in the mouse: participation of cAMP, steroid hormone, and a putative maturation-inhibitory factor. Dev Biol 1983, 100:39-49. 10.1016/0012-1606(83)90198-7, 6194027.
3. Schultz RM, Montgomery RR, Ward-Bailey PF, Eppig JJ. Regulation of oocyte maturatation in the mouse: possible roles of intercellular communication, cAMP, and testosterone. Dev Biol 1983, 95:294-304. 10.1016/0012-1606(83)90030-1, 6186544.
4. Anderiesz C, Trounson AO. The effect of testosterone on the maturation and development capacity of murine oocytes in vitro. Hum Reprod 1995, 10:2377-2381.
5. Qiao J, Feng HL. Extra- and intra-ovarian factors in polycystic ovary syndrome: impact on oocyte maturation and embryo developmental competence. Hum Reprod Update 2010, 17:17-33. 3001338, 20639519.
6. Romero S, Smitz J. Exposing cultured mouse ovarian follicles under increased gonadotropin tonus to aromatizable androgens influences the steroid balance and reduces oocyte meiotic capacity. Endocrine 2010, 38:243-253. 10.1007/s12020-010-9380-y, 21046485.
7. Li M, Schatten H, Sun Q-Y. Androgen receptor's destiny in mammalian oocytes: a new hypothesis. Molec Hum Reprod 2009, 15:149-154. 10.1093/molehr/gap006, 19193657.
8. Kimura S, Matsumoto T, Matsuyama R, Shiina H, Sato T, Takeyama K, Kato S. Androgen receptor function in folliculogenesis and its clinical implication in premature ovarian failure. Trends Endocrinol Metab 2007, 18:183-189. 10.1016/j.tem.2007.04.002, 17442585.
9. Laufer N. Role of androgens in the treatment of patients with low ovarian response. Reprod Biomed Online 2009, 19:888-898. 10.1016/j.rbmo.2009.09.012, 20031033.
10. Lenie S, Smitz J. Functional AR signaling is evident in an in vitro mouse follicle culture bioassay that encompasses most stages of folliculogenesis. Biol Reprod 2009, 80:685-695. 10.1095/biolreprod.107.067280, 19074005.
11. Lutz LB, Jamnongjit M, Yang W-H, Jahani D, Gill A, Hammes SR. Selective modulation of genomic and nongenomic androgen responses by androgen receptor ligands. Mol Endocrinol 2003, 17:1106-1116. 10.1210/me.2003-0032, 12637588.
12. White SN, Jamnongjit M, Gill A, Lutz LB, Hammes SR. Specific modulation of nongenomic androgen signaling in the ovary. Steroids 2005, 70:352-360. 10.1016/j.steroids.2005.02.008, 15862817.
13. Gelmann EP. Molecular biology of the androgen receptor. J Clin Oncol 2002, 20:3001-3015. 10.1200/JCO.2002.10.018, 12089231.
14. Yang MY, Fortune JE. Testosterone stimulates the primary to secondary follicle transition in bovine follicles in vitro. Biol Reprod 2006, 75:924-932. 10.1095/biolreprod.106.051813, 16943368.
15. Tetsuka M, Whitelaw PF, Bremner WJ, Millar MR, Smith CD, Hillier SG. Developmental regulation of androgen receptor in rat ovary. J Endocrinol 1995, 145:535-543. 10.1677/joe.0.1450535, 7636438.
16. Hillier SG, Tetsuka M, Fraser HM. Androgen receptor function in folliculogenesis and its clinical implication in premature ovarian failure. Hum Reprod 1997, 12:107-111. 10.1093/humrep/12.1.107, 9433966.
17. Weil SJ, Vendola K, Zhou J, Adesanya OO, Wang J, Okafor J, Bondy CA. Androgen receptor gene expression in the primate ovary: cellular localization, regulation, and functional correlations. J Clin Endocrinol Metab 1998, 83:2479-2485. 10.1210/jc.83.7.2479, 9661631.
18. Gleicher N, Weghofer A, Barad DH. Defining ovarian reserve to better understand ovarian aging. Reprod Biol Endocrinol 2011, 9:23. 10.1186/1477-7827-9-23, 3042920, 21299886.
19. Walters KA, Simanainen U, Handelsman FJ. Molecular insights into androgen actions in male and female reproductive function from androgen receptor knockout models. Hum Reprod Update 2010, 16:543-558. 10.1093/humupd/dmq003, 20231167.
20. Walters KA, McTavish KJ, Seneviratne MG, Jimenez M, McMahon AC, Allan CM, Salamonsen LA, Handelsman DJ. Subfertile female androgen receptor knockout mice exhibit defects in neuroendocrine signaling, intraovarian function, and uterine development but not uterine function. Endocrinology 2009, 150:3274-3282. 10.1210/en.2008-1750, 2703552, 19359383.
21. Sen A, Hammes SR. Granulosa-cell specific androgen receptors are critical regulators of ovarian development and function. Mol Endocrinol 2010, 24:1393-1403. 10.1210/me.2010-0006, 2903904, 20501640.
22. Li M, Ai J-S, Xu B-Z, Xiong B, Yin S, Lin S-L, Hou Y, Chen D-Y, Schatten H, Sun Q-Y. Testosterone potentially triggers meiotic resumption by activation of intra-oocyte SRC and MAPK in porcine oocytes. Biol Reprod 2008, 79:897-905. 10.1095/biolreprod.108.069245, 18667751.
23. Young JM, McNeilly AS. Theca: the forgotten cell of the ovarian follicle. Reproduction 2010, 140:489-504. 10.1530/REP-10-0094, 20628033.
24. Palermo R. Differential actions of FSH and LH during folliculogenesis. Reprod Biomed Online 2007, 15:326-337. 10.1016/S1472-6483(10)60347-1, 17854533.
25. Campbell BK, Baird DT, Webb R. Effects of dose of LH on androgen production and luteinization of ovine theca cells cultured in serum-free system. J Reprod Fertil 1998, 112:69-77. 10.1530/jrf.0.1120069, 9538331.
26. Shoham Z. The clinical therapeutic window for luteinizing hormone in controlled ovarian stimulation. Fertil Steril 2002, 77:1170-1177. 10.1016/S0015-0282(02)03157-6, 12057724.
27. Weghofer A, Gleicher N. Ovarian function: a theory of relativity. Hum Reprod 2009, 24:17-19.
28. Wu YG, Bennett J, Talla D, Stocco C. Testosterone, not 5{alpha} dihydrotestosterone, stimulates LRH-1 leading to FSH-independnet expression of Cyp 19 and P450scc in granulosa cells. Mol Endocrinol 2011, 25:656-658. 10.1210/me.2010-0367, 21273442.
29. Sánchez F, Adriaenssens T, Romero S, Smitz J. Different follicle-stimulating hormone exposure regimens during antral follicle growth alter gene expression in the cumulus-oocyte complex in mice. Biol Reprod 2010, 83:514-524. 10.1095/biolreprod.109.083311, 20592308.
30. Shi X, Li N, Liao C, Shu Q, Zhu F. Glucocorticoid or androgen for autoimmune premature ovary failure in mice. Zhong Nan Da Xue Xue Bao Yi Xue Ban 2009, 34:576-581.
31. Geva E, Amit A, Lerner-Geva L, Lessing JB. Autoimmunity and reproduction. Fertil Steril 1997, 67:599-611. 10.1016/S0015-0282(97)81351-9, 9093180.
32. Gleicher N, Barad DH. Gender as a risk factor for autoimmune diseases. J Autoimmun 2007, 28:1-6. 10.1016/j.jaut.2006.12.004, 17261360.
33. Gleicher N, Weghofer A, Lee IH, Barad DH. FMR1 genotype with autoimmunity-associated polycystic ovary-like phenotype and decrease pregnancy chance. PLoS ONE 2010, 5:(12): e15303. 3002956, 21179569.
34. Brzynski RG, Grow DR, Smith JA, Seltman HJ. Increase in androgen:estrogen ratio specifically during low dose follicle-stimulating hormone therapy for polycystic ovary syndrome. Fertil Steril 1995, 64:693-697.
35. Teissier MP, Chable H, Paulhac S, Aubard Y. Comparison of follicle steroidogenesis from normal and polycystic ovaries in women undergoing IVF: relationship between steroid concentrations, follicle size, oocyte quality and fecundability. Hum Reprod 2000, 15:;2471-2477. 10.1093/humrep/15.12.2471, 11263541.
36. Jabara S, Coutifaris C. In vitro fertilization in the PCOS patient: clinical considerations. Semin Reprod Med 2003, 21:317-324.
37. Nelson VL, Qin K, Rosenfield RL, Wood JR, Penning JMTM, Legro RS, Strauss JF, Mc Allister JM. The biochemical basis for increased testosterone production in theca calls propagated from patients with polycystic ovary syndrome. J Clin Endocrinol Metab 2001, 86:5925-5933. 10.1210/jc.86.12.5925, 11739466.
38. Dumesic DA, Padmanabhan V, Abbott DH. Polycystic ovary syndrome and oocyte development competence. Obstet Gynecol Surv 2007, 63:39-48.
39. Boomsma CM, Fauser BCJM, Macklon NS. Pregnancy complications in women with polycystic ovary syndrome. Semin Reprod Med 2008, 26:72-84. 10.1055/s-2007-992927, 18181085.
40. Heijnen EM, Eijkemans MJ, Hughes EG, Laven JS, Macklon NS, Fauser BC. A meta-analysis of outcomes of conventional IVF in women with polycystic ovary syndrome. Hum Reprod Update 2006, 12:13-21.
41. Sahu B, Ozturk O, Ranierri M, Serhal P. Comparison of oocyte quality and intracytoplasmic sperm injection outcome in women with isolated polycystic ovaries or polycystic ovarian syndrome. Arch Gynecol Obstet 2008, 277:239-244. 10.1007/s00404-007-0462-x, 17899140.
42. Kuivasaari-Pirinen P, Hippeläinen M, Hakkarainen H, Randell K, Heinonen S. Cumulative baby take-home rate among women with PCOS treated by IVF. Gynecol Endocrinol 2010, 26:582-589. 10.3109/09513591003632043, 20175706.
43. Nejad ES, Saedi T, Saedi S, Rashidi BH, Nekoo ZA, Jahangiri N. Comparison of in vitro fertilsation success in patients with Polycystic ovary syndrome and tubal factor. Gynecol Endocrinol 2011, 27:117-120. 10.3109/09513590.2010.501872, 20636232.
44. Weghofer A, Munné S, Chen S, Barad D, Gleicher N. Lack of association between polycystic ovary syndrome and embryonic aneuploidy. Fertil Steril 2007, 88:900-905. 10.1016/j.fertnstert.2006.12.018, 17433813.
45. Luchetti CG, Solano ME, Sander V, Arcos ML, Gonzalez C, Di Girolamo G, Chiocchio S, Cremaschi G, Motta AB. Effects of dehydroepiandrosterone on ovarian cystogenesis and immune function. J Reprod Immunol 2004, 64:59-74. 10.1016/j.jri.2004.04.002, 15596227.
46. Sander V, Lucchetti CG, Solano ME, Elia E, Di Girolamo G, Gonzalez C, Motta AB. Role of the N,N'-dimethylbiguanide metformin in the treatment of female prepuberal BALB/c mice hyperandrogenized with dehydroepiandrosterone. Reproduction 2006, 131:591-602. 10.1530/rep.1.00941, 16514202.
47. Barad DH, Gleicher N. Increased oocyte production after treatment with dehydroepiandrosterone. Fertil Steril 2005, 84:756.
48. Franks S, Stark J, Hardy K. Follicle dynamics and anovulation in polycystic ovary syndrome. Hum Reprod Update 2008, 14:367-368. 10.1093/humupd/dmn015, 18499708.
49. Patel SS, Carr BR. Oocyte quality in adult polycystic ovary syndrome. Semin Reprod Med 2008, 26:196-203. 10.1055/s-2008-1042958, 18302111.
50. Barad DH, Kim A. Correlation between functional ovarian reserve, assessed by anti-Müllerian hormone (AMH), and oocyte numbers, based on FMR1 genotypes and sub-genotypes: The hom sub-genotypes. Fertil Steril (ASRM Suppl); submitted.
51. Zhu J-Q, Zhu L, Liang X-W, Xing F-Q, Schatten H, Sun Q-Y. Demetyhylation of LHR in dehydroepiandrosterone-induced mouse model of polycystic ovary syndrome. Molec Hum Reprod 2010, 16:260-266. 10.1093/molehr/gap089, 19828691.
52. Van Nieuwerburgh F, Stoop D, Cabri P, Dhont M, Deforce D, De Sutter P. Shorter CAG repeats in the androgen receptor gene may enhance hyperandrogenicity in polycystic ovary syndrome. Gynecol Endocrinol 2008, 24:669-673. 10.1080/09513590802342841, 19172534.
53. Liu H, Hong J, Cui B, Zhang Y, Gu W, Chi Z, Su Y, Ning G. Androgen receptor gene CAG(n) trinucleotide repeats polymorphism in Chinese women with polycystic ovary syndrome. Endocrine 2008, 33:165-170. 10.1007/s12020-008-9069-7, 18483883.
54. Jääskeläinen J, Korhonen S, Kuulasmaa T, Kurl S, Niskanen L, Vanhala M, Hippeläinen M, Voutilainen R, Heinonen S. Androgen receptor gene CAG repeat length in women with metabolic syndrome. Gynecol Endocrinol 2008, 24:411-416. 10.1080/09513590802210865, 18645714.
55. Ferk P, Perme MP, Teran N, Gersak K. Androgen receptor gene (CAG)n polymorphism in patients with polycystic ovary syndrome. Fertil Steril 2008, 90:860-863. 10.1016/j.fertnstert.2007.07.1291, 18555222.
56. Gleicher N, Weghofer A, Lee IH, Barad DH. Association of FMR1 genotypes with in vitro fertilization (IVF) outcomes based on ethnicity/race. PLoS ONE 6(4):e18781.
57. Dasgupta S, Sirisha PVS, Neelaveni K, Anuradha K, Reddy AG, Thangaraj K, Reddy BM. Androgen receptor CAG repeat polymorphism and epigenetic influence among the South Indian Women with polycystic ovary syndrome. PLoS ONE 5(8):e12401.
58. Yang J-L, Zhang C-P, Li L, Huang L, Ji S-Y, Lu C-L, Fan C-H, Cai H, Ren Y, Hu Z-Y, Gao F, Liu Y-X. Testosterone induces redistribution of Forkhead box-3a and down regulation of growth and differentiation factor 9 messenger ribonucleic acid expression at early stage of mouse folliculogenesis. Endocrinology 2010, 151:774-782. 10.1210/en.2009-0751, 20032061.
59. Qureshi AI, Nussey SS, Bano G, Musonda P, Whitehead SA, Mason HD. Testosterone selectively increases primary follicles in ovarian cortex grafted onto embryonic chick membranes: relevance to polycystic ovaries. Reproduction 2008, 136:187-194. 10.1530/REP-07-0172, 2754341, 18456904.
60. Gleicher N, Barad DH. Dehydroepiandrosterone (DHEA) supplementation in diminished ovarian reserve (DOR). Reprod Biol Endocrin
61. Lee MT, Anderson E, Lee GY. Changes in ovarian morphology and serum hormones in the rat after treatment with dehydroepiandrosterone. Anat Rec 1991, 231:185-192. 10.1002/ar.1092310206, 1836118.
62. Belgorosky D, Sander VA, Yorio MP, Faletti AG, Motta AB. Hyperandrogenism alters intraovarian parameters during early folliculogenesis in mice. Reprod Biomed Online 2010, 20:797-807. 10.1016/j.rbmo.2010.02.012, 20362510.
63. Elia E, Sander V, Luchetti CG, Solano ME, Di Girolamo G, Gonzalez C, Motta AB. The mechanism involved in the action of metformin in regulating ovarian function in hyperandrogenized mice. Molec Hum Reprod 2006, 12:4750481.
64. Chang C, Gershwine ME. Drug-induced lupus erythematosus: incidence, management and prevention. Drug Saf 2011, 34:357-374. 10.2165/11588500-000000000-00000, 21513360.
65. Chen X, Oppenheim JJ. Contrasting effects of TNF and anti-TNF on the activation of effector T cells and regulatory T cells in autoimmunity. FEBS Lett 2011,
66. Casson PR, Lindsay MS, Pisarska MD, carson SA, Buster JE. Dehydroepiandrosterone aupplementation augments ovarian stimulation in poor responders; a case series. Hum Reprod 2000, 15:2129-2132. 10.1093/humrep/15.10.2129, 11006185.
67. Casson PR, Santoro N, Elkind-Hirsch K, Carson SA, Hornsby PJ, Abraham G, Buster JE. Postmenopausal DHEA administration increases free insulin-like growth factor - I and decreases high-density lipoprotein: a six-month trial. Fertil Steril 1998, 70:107-110. 10.1016/S0015-0282(98)00121-6, 9660430.
68. Barad D, Gleicher N. Effect of dehydroepiandrosterone on oocyte and embryo yields, embyo grade and cell number in IVF. Hum Reprod 2006, 21:2845-2849. 10.1093/humrep/del254, 16997936.
69. Barad DH, Brill H, Gleicher N. Update on the use of dehydroepiandrosterone supplementation among women with diminished ovarian function. J Assist Reprod Genet 2007, 24:629-634. 10.1007/s10815-007-9178-x, 18071895.
70. Wiser A, Gonen O, Ghetler Y, Shavit T, Berkovitz A, Shulman A. Addition of dehydroepiandrosterone (DHEA) for poor-respoder patients before and during IVF treatment improves the pregnancy rate: a randomized prospective study. Hum Reprod 2010, 25:2496-2500. 10.1093/humrep/deq220, 20729538.
71. Gleicher N, Weghofer A, Barad DH. Improvement in diminished ovarian reserve after dehydroepiandrosterone supplementation. Reprod Biomed Online 2010, 21:360-365. 10.1016/j.rbmo.2010.04.006, 20638339.
72. Lossl K, Andersen AN, Loft A, Freisesleben NK, Bangsbøll S, Andersen CY. Androgen priming using aromatase inhibitor and hCG during early-follicular phase GnRH antagonist down-regulation in modified antagonist protocol. Hum Reprod 2006, 21:2593-2600. 10.1093/humrep/del221, 16785262.
73. Lossl K, Andersen CY, Loft A, Freiesleben NL, Bangsbøll S, Andersen AN. Short-term androgen priming with use of aromatase inhibitor and hCG before controlled ovarian stimulation for IVF. A randomized controlled trial. Hum Reprod 2008, 23:1820-1929. 10.1093/humrep/den131, 18487212.
74. Frattarelli JL, Peterson EH. Effect of androgen levels on in vitro fertilization cycles. Fertil Steril 2004, 81:1713-1714. 10.1016/j.fertnstert.2003.11.032, 15193506.
75. Frattarelli JL, Gerber MD. Basal and cycle androgen levels correlate with in vitro fertilization stimulation parameters but do not predict pregnancy outcome. Fertil Steril 2006, 86:51-57. 10.1016/j.fertnstert.2005.12.028, 16716312.
76. Massin N, Cedrin-Durnerin I, Coussieu C, Galey-Fontaine J, Wolf JP, Hugues JN. Effects of transdermal testosterone application on the ovarian response to FSH in poor responders undergoing assisted reproductive-technique - a prospective randomized, double blind study. Hum Reprod 2006, 21:1204-1211. 10.1093/humrep/dei481, 16476678.
77. Balasch J, Fábreques F, Peñarurubia J, Carmona F, Casamitjana R, Creus M, Manau D, Casals G, Vanrell JA. Pretreatment with transdermal testosterone may improve ovarian response to gonadothrophins in poor-responder IVF patients with normal baseline concentration of FSH. Hum Reprod 2006, 21:; 1884-1893.
78. Fábreques F, Peñarurubia J, Creus M, Manu D, Caals G, Carmone F, Balasch J. Transdermal testosterone may improve ovarian response to gonadotrophins in low-repsonder IVF patients: a randomized, clinical trial. Hum Reprod 2009, 24:349-359. 10.1093/humrep/den428, 19054777.
79. Sipe CS, Van Voorhis BJ. Testosterone patch improves ovarian follicular response to gonadotrophins in a patient with Kallmann's syndrome: a case report. Hum Reprod 2007, 22:1380-1383. 10.1093/humrep/dem009, 17341590.
80. Sipe CS, Thomas MR, Stegman BJ, Van Voorhis BJ. Effects of exogenous testosterone supplementation in gonadotrophin stimulated cycles. Hum Reprod 2010, 25:690-696. 10.1093/humrep/dep442, 20031956.
81. Hossein Rashidi B, Hormoz B, Shahrokh Tehraninejad E, Shariat M, Mahdavi A. Testosterone and dehydroepiandrosterone sulfate levels and IVF/ICSI results. Gynecol Endocrin 2009, 25:194-198.
82. Qin Y, Zhao Z, Sun M, Geng L, Che L, Chen Z-J. Association of basal serum testosterone levels with ovarian response and in vitro fertilization outcome. Reprod Biol Endocrin 2011, 9:9.
83. Kim C-H, Howles CM, Lee H-A. The effect of transdermal testosterone gel pretreatment on controlled ovarian stimulation and IVF outcome in low responders. Fertil Steril 2011, 95:679-683. 10.1016/j.fertnstert.2010.07.1077, 20801436.
84. Homburg R. Androgen circle of polycystic ovary syndrome. Hum Reprod 2009, 24:1548-1555. 10.1093/humrep/dep049, 19279033.
85. Li M, Ai JS, Xu BZ, Xiong B, Tin S, Lin SL, Hou Y, Chen DY, Schatten H, Sun Q. Testosterone potentially triggesr meiotic resumption by avtivation of intra-oocyte SRC and MAPK in porcine oocyte. Domest Anim Endocrinol 2008, 34:360-371. 10.1016/j.domaniend.2007.10.001, 18023131.
86. Casson PR, Kristiansen SB, Umstot EE, Carson SA, Buster JE. Ovarian hyperstimulation augments adrenal dehydroepiandrosterone sulfate secretion. Fertil Steril 1996, 65:950-953.
87. Wang H, Andoh K, Hagiwara H, Xiaowei L, Kikuchi N, Abe Y, Yamada K, Fatima R, Mizunuma H. Effect of adrenal and ovarian androgens on type 4 follicles unresponsive to FSH in immature mice. Endocrinol 2001, 142:4930-4936.
88. Gleicher N, Weghofer A, Barad DH. Anti-Müllerian hormone (AMH) defines, independent of age, low versus good live birth chances in women with severely diminished ovarian reserve. Fertil Steril 2010, 94:2824-2827. 10.1016/j.fertnstert.2010.04.067, 20538269.
89. Weghofer A, Dietrich W, Barad D, Gleicher N. Live birth chances in women with extremely low serum anti-Müllerian hormone levels. Hum Reprod 2011,
90. Gleicher N, Ryan E, Weghofer A, Blanco-Meija S, Barad DH. Miscarriage rates after dehydroepiandrosterone (DHEA) supplementation in women with diminished ovarian reserve: a case control study. Reprod Biol Endocinol 2009, 7:108.
91. Gleicher N, Weghofer A, Barad DH. Dehydroepiandrosterone (DHEA) reduces embryo aneuploidy: direct evidence from preimplantation genetic screening (PGS). Reprod Biol Endocrinol 2010, 8:140. 10.1186/1477-7827-8-140, 2992540, 21067609.
92. Gleicher N, Weghofer A, Barad DH. Defining ovarian reserve to better understand ovarian aging. Reprod Biol Endocrinol 2011, 9:23. 10.1186/1477-7827-9-23, 3042920, 21299886.
93. Jacob MH, da R Janner D, Jahn MP, Kucharski LB, Belló-Klein A, Ribeiro MF. Age-related effects of DHEA on peripheral makers of oxidative stress. Cell Biochem Funct 2010, 28:52-57. 10.1002/cbf.1619, 19924683.
94. Sowers MFR, Zheng H, McConnell D, Nan B, Karvonen-Guiterez CA, Randolph JF. Testosterone, sex hormone-binding globulin and free androgen index among adult women: chronological and ovarian aging. Hum Reprod 2009, 24:2276-2285. 10.1093/humrep/dep209, 2733826, 19520711.
95. Barad DH, Weghofer A, Gleicher N. Age-specific levels of basal follicle-stimulating hormone assessment of ovarian function. Obstet Gynecol 2007, 109:1404-1410. 10.1097/01.AOG.0000264065.37661.a0, 17540814.
96. Gleicher N, Kubba H, Weghofer A. Hormonal contraception prior to in vitro fertilization (IVF) adversely affects functional ovarian reserve and oocyte yields. Fertil Steril (ASRM Suppl), submitted.
97. Coccia ME, Rizzello F. Ovarian reserve. An NY Acad Sci 2008, 1127:27-30.
98. Broekmans FJ, Soules MR, fauser BC. Ovarian aging: mechanisms and clinical consequences. Endocr Rev 2009, 30:465-493. 10.1210/er.2009-0006, 19589949.
99. Hodges CA, Ilagan A, Jenninger D, Keri R, Nilson J, Hunt PA. Experimental evidence that changes in oocyte growth influence meiotic chromosome segregation. Hum Reprod 2002, 17:1171-1180. 10.1093/humrep/17.5.1171, 11980735.
100. Sá R, Neves R, Fernandes S, Alves C, Carvalho F, Silva J.
101. Bentov Y, Esfandiari N, Burstein E, Casper RF. The use of mitochondrial nutrients to improve the outcome of infertility treatment in older patients. Fertil Steril 2010, 93:272-275. 10.1016/j.fertnstert.2009.07.988, 19732879.
102. Malheiro I, Barros A, Sousa M. Cytological and expression studies and quantitative analysis of the temporal and stage-specific effects of follicle-stimulating hormone and testosterone during cocultures of the normal human seminiferous epithelium. Biol Reprod 2008, 79:962-975. 10.1095/biolreprod.107.067546, 18667755.